🇺🇸 FDA
Patent

US 7731971

Enhanced CTL epitope-containing HIV-1 reverse transcriptase polypeptides

granted A61KA61K2039/5158A61K2039/53

Quick answer

US patent 7731971 (Enhanced CTL epitope-containing HIV-1 reverse transcriptase polypeptides) held by The United States of America as Represented by the Secretary of the Department of Health and Human Services expires Mon Jun 03 2030 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America as Represented by the Secretary of the Department of Health and Human Services
Grant date
Tue Jun 08 2010 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 03 2030 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
27
CPC classes
A61K, A61K2039/5158, A61K2039/53, A61K2039/54, A61K2039/545